SIRT1激活胎儿血红蛋白基因表达
本研究在人类红系细胞和K562细胞中发现,去乙酰化酶SIRT1可诱导γ-珠蛋白基因(HBG)表达;SIRT1小分子激活剂SRT2104和SRT1720可增强脐血红系母细胞HBG表达并重新激活成人红系母细胞中沉默的HBG。SIRT1通过促进LCR环化至HBG启动子、抑制HBG转录抑制因子表达及增加启动子组蛋白乙酰化发挥作用,且不改变红系祖细胞增殖或CD235a表达。
要点
- SIRT1敲低降低而异位表达上调原代人红系细胞和K562细胞中HBG表达。
- SRT2104和SRT1720增强脐血红系母细胞HBG表达并重新激活成人红系母细胞沉默HBG。
- SIRT1结合β-珠蛋白基因簇LCR和HBG启动子,促进LCR与HBG启动子环化。
核心结论
- SIRT1通过促进LCR环化至HBG启动子、抑制HBG转录抑制因子表达及间接增加HBG启动子组蛋白乙酰化来激活HBG表达。
- SIRT1是γ-珠蛋白基因诱导的潜在治疗靶点,小分子SIRT1激活剂可能作为开发新型HbF诱导剂的先导化合物。
研究设计与样本
- 研究在原发性人红系细胞和K562细胞中进行SIRT1敲低与异位表达实验。
- 使用小分子SIRT1激活剂SRT2104和SRT1720处理脐血人红系母细胞和成人红系母细胞。
主要发现
- SIRT1敲低降低而SIRT1异位表达上调原代人红系细胞和K562细胞中γ-珠蛋白基因(HBG)表达。
- SRT2104和SRT1720增强脐血人红系母细胞HBG表达并重新激活成人红系母细胞中沉默的HBG。
- SIRT1结合于β-珠蛋白基因簇 locus control region(LCR)和HBG启动子,促进LCR与HBG启动子环化,并增加HBG启动子中RNA聚合酶II和H4K16Ac的结合。
- SIRT1抑制HBG抑制因子BCL11A、KLF1、HDAC1和HDAC2的表达。
- SIRT1不改变人红系祖细胞增殖或分化标志CD235a表达。
关键数值与推荐
- SIRT1敲低降低HBG表达,SIRT1异位表达上调HBG表达(原代人红系细胞和K562细胞)。
- SRT2104和SRT1720增强脐血人红系母细胞HBG表达并重新激活成人红系母细胞沉默HBG。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High fetal hemoglobin (HbF, α2 γ2 ) levels ameliorate the clinical manifestations of sickle cell disease and β thalassemia. The mechanisms that repress HbF expression and silence γ-globin genes in adults are incompletely characterized and only a single HbF inducer, hydroxyurea, is approved for treatment, and only in patients with sickle cell disease. We identified SIRT1, a protein deacetylase, as a new inducer of γ-globin. SIRT1 knockdown decreased, while SIRT1 ectopic expression upregulated γ-globin gene (HBG) expression in primary human erythroid cells and in K562 cells. The small molecule SIRT1 activators SRT2104 and SRT1720 enhanced HBG expression in cord blood human erythroblasts and reactivated silenced HBG in adult human erythroblasts. Furthermore, SIRT1 binds in the β-globin gene cluster locus control region (LCR) and HBG promoters, promotes the looping of the LCR to HBG promoter, and increases the binding of RNA polymerase II and H4K16Ac in the HBG promoter. SIRT1 suppressed the expression of the HBG suppressors BCL11A, KLF1, HDAC1 and HDAC2. Lastly, SIRT1 did not change the proliferation of human erythroid progenitor cells or the expression of differentiation marker CD235a. These data suggest that SIRT1 activates HBG expression through facilitating LCR looping to the HBG promoter, inhibiting the expression of transcriptional suppressors of HBG, and indirectly increasing histone acetylation in the HBG promoter. SIRT1 is a potential therapeutic target for γ-globin gene induction, and small molecule SIRT1 activators might serve as a lead compound for the development of new HbF inducers.
引用
- Dai Y, Chen T, Ijaz H, et al. SIRT1 activates the expression of fetal hemoglobin genes. Am J Hematol. 2017. PMID: 28776729. doi:10.1002/ajh.24879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。